|
Please read this informative blog post by clinical microbiology and postdoctoral fellow, Thea Brennan-Krohn: "AST FOR NEW ANTIBIOTICS: THE CLINICAL LABORATORIAN'S DILEMMA."
0 Comments
The manuscript highlights the remarkable activity of apramycin against multidrug-resistant, extensively drug resistant and pandrug-resistant Acinetobacter and Pseudomonas. Both organisms are significant multidrug-resistance threats. Importantly, frank resistance to apramycin was observed in < 2% of isolates. Apramycin is an aminocyclitol-based aminoglycoside that is currently approved for veterinary use. The activity in these groups of bacteria was especially notable in light of the high level of resistance of the same strain set to aminoglycosides (amikacin, gentamicin, tobramycin) approved for human use. This study complements our prior study, also published in DMID, demonstrating activity of apramycin against a high proportion of carbapenem-resistant Enterobacteriaceae strains.
Published online today in Infection and Immunity: "Promotion and Rescue of Intracellular Brucella neotomae Replication During Co-Infection With Legionella pneumophila." Yoon-Suk created a versatile bioreporter toolkit to enable analysis of the fate of individual pathogens in polymicrobial infections. He then validated a type IV secretion system-dependent Brucella model using the wood rat pathogen, Brucella neotomae. In contrast to wild type organisms, Brucella T4SS mutants were completely defective in their ability to growth inside of macrophages. Fascinatingly co-infection with Legionella pneumophila, another T4SS-dependent pathogen, was able to rescue intracellular growth of the T4SS-mutant Brucella and also stimulated growth of wild type Brucella organisms! This was a one way rescue: Legionella could rescue Brucella, but wild type Brucellla could not rescue T4SS-defective Legionella.
Our antimicrobial susceptibility testing research is highlighted on Harvard Catalyst Spotlight3/6/2017 See discussion of our work on Microscopy-Based Antimicrobial Susceptibility Testing as part of the Harvard Catalyst Reactor Pilot Program.
Thea received an ASM Infectious Disease Travel Award and KP Smith an ASM Postdoctoral Travel Award. Both prestigious ASM Travel Awards are based on abstract submissions to the 2017 ASM MIcrobe Meeting in New Orleans. Jennifer Tsang will be joining the crew with an abstract acceptance on her high throughput screening work..
Here is the link to to the STAT Madness competition: www.statnews.com/feature/stat-madness/bracket/. Please vote for BIDMC in the line up. Our research on discovery of antimicrobials targeting carbapenem-resistant Enterobacteriaceae is highlighted. See "Validation of a High-Throughput Screening Assay for Identification of Adjunctive and Directly Acting Antimicrobials Targeting Carbapenem-Resistant Enterobacteriaceae" published in Assay and Drug Development Technologies and accompanying editorial for more information."
|
Kirby Lab Blog Categories
All
Archives
November 2019
|
RSS Feed